A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

Inclusion Criteria: * Female at birth. * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 27.0 kilograms per square meter (kg/m\^2) and 39.9 kg/m\^2 (both inclusive) at screening. * Overweight should be due to excess adipose tissue, as judged by the investigator. * Considered eligible with suitable veins for cannulation or repeated venepuncture, as judged by the investigator. * No clinically significant findings during medical history, physical examination, vital signs, electrocardiogram or clinical laboratory tests at the screening visit, as assessed by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method. * Current participation (i.e., dosing) in any other interventional clinical study within 90 days before screening. * Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening, including incretin-based treatment(s). * Previous or planned (during the study period) obesity treatment with surgery. However, the following are allowed: 1. Liposuction and/or abdominoplasty, if performed greater than symbol (\>) 1 year before screening. 2. Adjustable gastric banding, if the band has been removed \> 1 year before screening. 3. Intragastric balloon, if the balloon has been removed \> 1 year before screening. 4. Duodenal-jejunal bypass liner (e.g., Endobarrier), if the sleeve has been removed \> 1 year before screening.